events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
Search
Login
events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
Login
News and Community
Alzheimer’s Diagnostics
,
Alzheimer’s Disease Testing
,
Blood Biomarkers
,
Blood-based Neurology Testing
,
Clinical Diagnostics
,
Cognitive Decline
,
Fujirebio
,
Healthcare Technology
,
Ivd Testing
,
Lumipulse G
,
Neurological Biomarkers
,
Neurological Disease
,
Neurology Diagnostics
,
Nfl Biomarker
,
Ptau 217
September 14, 2026
Fujirebio Gains ANVISA Authorization in Brazil for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma
Inbrija
,
Jiangxi Kvvit Pharmaceutical
,
Levodopa Inhalation Powder
,
Merz Therapeutics
,
Neurological Disease
,
Parkinson's Disease
May 26, 2026
Merz Therapeutics and Kvvit Sign Exclusive Agreement for INBRIJA (levodopa inhalation powder) in Mainland China, Hong Kong, and Macao
Load More
